A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Exclusion Criteria

• •Prior use of monoclonal antibody within 4 weeks before Cycle 1, Day 1
• •Treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1
• •Toxicities from any previous treatment must be resolved prior to Cycle 1, Day 1, except for neuropathy
• •Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1
• •Prior allogeneic stem cell transplant
• •History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
• •Grade \> 1 peripheral neuropathy
• •Active infection at screening or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to Cycle 1, Day 1
• •Positive for hepatitis B, hepatitis C or HIV infection
• •Pregnant or lactating women or women who intend to become pregnant within the period of time of this study